Accumulation of technetium-99m pertechnetate in a patient with metastases of thyroid carcinoma

Yamamoto, Yuka; Nishiyama, Yoshihiro; Ono, Yuko; Satoh, Katashi; Ohkawa, Motoomi; Kawasaki, Yukiko; Tanabe, Minoru

doi:10.1007/bf03164877

Cited by 8 publications

(4 citation statements)

References 10 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differentiating a benign follicular adenoma from a malignant follicular carcinoma is challenging by cytology, and a thyroid scan is advocated in these cases, considering functioning nodules as being benign [1, 21]. Hot nodules outside the thyroid can be helpful in diagnosis of malignancy in the case of metastatic thyroid carcinoma, but this is rare in practice [22]. In our patient, surgical treatment was preferred to radioiodine ablation considering her symptoms and the nodule's size.…”

Section: Discussionmentioning

confidence: 99%

Hyperfunctioning Solid/Trabecular Follicular Carcinoma of the Thyroid Gland

Giovanella

Fasolini

Suriano

et al. 2010

Journal of Oncology

View full text Add to dashboard Cite

A 68-year-old woman with solid/trabecular follicular thyroid carcinoma inside of an autonomously functioning thyroid nodule is described in this paper. The patient was referred to our clinic for swelling of the neck and an increased pulse rate. Ultrasonography showed a slightly hypoechoic nodule in the right lobe of the thyroid. Despite suppressed TSH levels, the 99mTc-pertechnetate scan showed a hot area corresponding to the nodule with a suppressed uptake in the remaining thyroid tissue. Histopathological examination of the nodule revealed a solid/trabecular follicular thyroid carcinoma. To the best of our knowledge, this is the first case of hyperfunctioning follicular solid/trabecular carcinoma reported in the literature. Even if a hyperfunctioning thyroid carcinoma is an extremely rare malignancy, careful management is recommended so that a malignancy will not be overlooked in the hot thyroid nodules.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperfunctioning Solid/Trabecular Follicular Carcinoma of the Thyroid Gland

Giovanella

Fasolini

Suriano

et al. 2010

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Most studies of 99m Tc-pertechnetate scans in patients with DTC mainly focused on the diagnostic efficiency of thyroid remnant or predicted value of lowto intermediate-risk DTC's therapy response to RAI therapy [7][8][9]. In postoperative 99m Tc-pertechnetate scan, 99m Tcpertechnetate avidity of DTC metastatic lesions is a rare phenomenon, only described by case reports [10][11][12][13][14][15], in which the 99m Tc-pertechnetate-avid metastatic foci were detected serendipitously. Some literature described the clinical characteristics of 99m Tc-pertechnetate-avid metastatic foci in DTC, including distant metastasis like lung and bone [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Unexpected 99mTc-pertechnetate avidity of lymph node metastases redicts better response to radioiodine therapy in differentiated hyroid cancer patients with lymph node metastases

Liu

2024

Am J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Objective: To investigate the value of 99m Tc-pertechnetate scan in postoperative differentiated thyroid cancer (DTC) patients with lymph node (LN) metastases (LNM) uptake 99m Tc-pertechnetate, especially the predictive value to their response to radioiodine-131 ( 131 I) therapy. Methods: This retrospective study collected 752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017. Depending on the ability of LNM uptake 99m Tc-pertechnetate, the patients were grouped as the 99m Tcpertechnetate-avid (n=88) vs. 99m Tc-pertechnetate-non-avid (n=664) groups. And Propensity score matching (PSM) was performed at a 1:4 ratio to reduce confounding bias. Results: In the PSM analysis, the 1:4 matched cohort comprised 752 patients (88 with 99m Tcpertechnetate-avid LNM, 664 with 99m Tc-pertechnetate-non-avid LNM). Patients' age, initial 131 I activity and frequency of iodine therapy were included as covariates. After PSM analysis, 363 patients ( 99m Tc-pertechnetate-avid group, n=83; 99m Tc-pertechnetate-non-avid group, n=280) were successfully matched. Among the 363 PSM-matched patients, 48/83 (57.8%) in the 99m Tc-pertechnetate-avid group and 158/280 (56.4%) in the 99m Tc-pertechnetate-non-avid group had two or more 131 I treatments. The nsTg and the percentage of changes in ssTg between the 99m Tc-pertechnetate-avid and 99m Tc-pertechnetate-non-avid groups were significantly different ([0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), p=0.018] and [-88% (-98%, -50%) vs. -66% (-86%, -30%), p < 0.001], respectively). No significant differences were observed between the two groups in the other parameters (age, pathological type, distant metastasis, follow-up time, AJCC TNM stage, initial 131 I treatment activity, and 131 I treatment frequency) after PSM (all p > 0.05). Conclusion: In patients with DTC and LNM, LNM uptake of 99m Tc-pertechnetate is a rare phenomenon. Patients with 99m Tc-pertechnetate-avid LNMs were more likely to benefit from 131 I therapy, even after adjustment for age, 131 I treatment frequency, and initial 131 I activity.

show abstract

“… 6 Over the last few decades, extra-thyroid 99m Tc-pertechnetate uptake has rarely been reported. 7 , 8 Furthermore, almost all available literature includes case reports, 9 – 14 most of which confirmed DTC metastases.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of extra-thyroid ^99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma

et al. 2021

View full text Add to dashboard Cite

Objective To analyse the clinical characteristics of extra-thyroid 99mTc-pertechnetate uptake in order to explore the effect of the phenomenon on radioactive iodine (RAI) therapy for differentiated thyroid carcinoma (DTC) and its clinical significance. Methods This study retrospectively selected patients with DTC and extra-thyroid 99mTc-pertechnetate uptake. The clinical features, location, location count and extra-thyroid 99mTc-pertechnetate uptake distribution were analysed, combined with the uptake rate, stimulated thyroglobulin (sTg) level, post-therapy whole-body scan and curative effect. Results A total of 38 patients were enrolled in the study and 65 extra-thyroid 99mTc-pertechnetate foci were detected. Thirty-four patients showed abnormal 99mTc-pertechnetate uptake in the lymph nodes (26 of 38; 68.4%), lungs (four of 38; 10.5%) and bones (four of 38; 10.5%). The corresponding uptake rates were 0.2%, 0.2% and 0.8%, respectively. The uptake rate and sTg were significantly positively correlated ( r = 0.36). 131I uptake was found in 36 patients at the 99mTc-pertechnetate uptake site. The number of iodine uptake foci was significantly higher than that of 99mTc-pertechnetate uptake foci. The sTg value and pathological staging significantly differed between the excellent and nonexcellent response groups (Z = –2.947 and Z = –2.348, respectively). Conclusion Extra-thyroid 99mTc-pertechnetate uptake mostly indicated metastases with specific clinical features, which may have prognostic value for the judgment of iodine uptake function and the RAI therapy plan.

show abstract

Accumulation of technetium-99m pertechnetate in a patient with metastases of thyroid carcinoma

Cited by 8 publications

References 10 publications

Hyperfunctioning Solid/Trabecular Follicular Carcinoma of the Thyroid Gland

Hyperfunctioning Solid/Trabecular Follicular Carcinoma of the Thyroid Gland

Unexpected 99mTc-pertechnetate avidity of lymph node metastases redicts better response to radioiodine therapy in differentiated hyroid cancer patients with lymph node metastases

Clinical significance of extra-thyroid ^99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma

Contact Info

Product

Resources

About

Accumulation of technetium-99m pertechnetate in a patient with metastases of thyroid carcinoma

Cited by 8 publications

References 10 publications

Hyperfunctioning Solid/Trabecular Follicular Carcinoma of the Thyroid Gland

Hyperfunctioning Solid/Trabecular Follicular Carcinoma of the Thyroid Gland

Unexpected 99mTc-pertechnetate avidity of lymph node metastases redicts better response to radioiodine therapy in differentiated hyroid cancer patients with lymph node metastases

Clinical significance of extra-thyroid 99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma

Contact Info

Product

Resources

About

Clinical significance of extra-thyroid ^99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma